MARKET

COCP

COCP

COCRYSTAL PHARMA
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.060
+0.040
+3.92%
Pre Market: 1.040 -0.02 -1.89% 09:25 09/24 EDT
OPEN
1.020
PREV CLOSE
1.020
HIGH
1.070
LOW
1.020
VOLUME
10.13K
TURNOVER
--
52 WEEK HIGH
3.460
52 WEEK LOW
0.7600
MARKET CAP
103.32M
P/E (TTM)
-7.0573
1D
5D
1M
3M
1Y
5Y
Cocrystal Pharma to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
BOTHELL, Wash., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company, announces that management will present at the 23rd Annual Global Investment Conference being h...
GlobeNewswire · 09/07 12:00
New COVID-19 Vaccination Mandates Make Rapid COVID Tests More Essential Than Ever
/PRNewswire/ -- With the number of new COVID cases surging, fueled by a highly contagious Delta variant and only 50% of the US population having been vaccinated, the need for rapid testing and treatments is more important than ever. Perhaps even more alarm...
PR Newswire - PRF · 08/19 12:50
Sabby Management, Llc Buys Cocrystal Pharma Inc, Enochian BioSciences Inc, Aterian Inc, Sells ...
GuruFocus News · 08/18 14:38
Cocrystal Pharma, Inc. (COCP) Reports Q2 Loss, Misses Revenue Estimates
Zacks.com · 08/16 13:25
BRIEF-Cocrystal Pharma Reports Q2 Loss Per Share $0.04
reuters.com · 08/16 12:26
Cocrystal Pharma Q2 EPS $(0.04) Up From $(0.07) YoY
Cocrystal Pharma (NASDAQ:COCP) reported quarterly losses of $(0.04) per share. This is a 42.86 percent increase over losses of $(0.07) per share from the same period last year.
Benzinga · 08/16 12:23
Cocrystal Pharma Reports Second Quarter 2021 Financial Results and Provides Antiviral Program and Milestone Updates
Influenza program Phase 1 clinical trial with CC-42344 on track to begin in the third quarter of 2021COVID-19 program preclinical development with the novel oral SARS-CoV-2 protease inhibitors is advancingTwo IND-enabling studies in the COVID-19 program ex...
GlobeNewswire · 08/16 12:00
ACADIA (ACAD) Q2 Earnings Beat, Revenues Miss Estimates
Zacks.com · 08/05 16:53
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of COCP. Analyze the recent business situations of COCRYSTAL PHARMA through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average COCP stock price target is 4.333 with a high estimate of 5.00 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 50
Institutional Holdings: 20.00M
% Owned: 20.52%
Shares Outstanding: 97.47M
TypeInstitutionsShares
Increased
14
1.77M
New
15
10.31M
Decreased
6
1.76M
Sold Out
6
65.32K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.99%
Pharmaceuticals & Medical Research
+1.27%
Key Executives
President/Co-Chief Executive Officer
Sam Lee
Co-Chief Executive Officer/Chief Financial Officer
James Martin
Director
Roger Kornberg
Director
Richard Pfenniger
Independent Director
Phillip Frost
Independent Director
Anthony Japour
Independent Director
Steven Rubin
No Data
About COCP
Cocrystal Pharma, Inc. is a biotechnology company. The Company focuses on developing antiviral therapeutics that inhibit the essential viral replication function of RNA viruses causing acute and chronic viral diseases. The Company focuses on treating influenza virus, coronavirus, and norovirus infections by discovering and developing drug candidates targeting the viral replication process. The Company uses computational methods to screen and design product candidates using cocrystal structural information. The Company’s Hepatitis C Virus (HCV) Non-Nucleoside Polymerase Inhibitor CC-31244 is a pan-genotypic inhibitor of NS5B polymerase for the treatment of hepatitis C infection. The Company’s CC-42344 is a PB2 inhibitor for the treatment of influenza A infection. It has also developed chemical libraries consisting of non-nucleoside inhibitors, metal-binding inhibitors, and drug-like fragments.

Webull offers kinds of Cocrystal Pharma Inc stock information, including NASDAQ:COCP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, COCP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading COCP stock methods without spending real money on the virtual paper trading platform.